Cargando…

Hypothyroidism and Nonalcoholic Fatty Liver Disease: Pathophysiological Associations and Therapeutic Implications

Nonalcoholic fatty liver disease (NAFLD) is a complex clinical entity which can be secondary to many other diseases including hypothyroidism, characterized by lowering of thyroid hormones and increased thyroid stimulating hormone (TSH). A lot of emerging data published recently advocates the hypothe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kizivat, Tomislav, Maric, Ivana, Mudri, Dunja, Curcic, Ines Bilic, Primorac, Dragan, Smolic, Martina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	XIA & HE Publishing Inc. 2020
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7562794/ https://www.ncbi.nlm.nih.gov/pubmed/33083258 http://dx.doi.org/10.14218/JCTH.2020.00027

Ejemplares similares

IMPACT OF GRAVES’ DISEASE AND ANTITHYROID DRUG THERAPY ON BONE MINERAL DENSITY – PATHOPHYSIOLOGICAL MECHANISMS AND CLINICAL RELEVANCE
por: Mudri, Dunja, et al.
Publicado: (2022)

Wnt Inhibitors and Bone Mineral Density in Patients with Graves’ Disease Treated with Antithyroid Drugs: A Preliminary Prospective Study
por: Mudri, Dunja, et al.
Publicado: (2022)

Hyperthyroidism and Wnt Signaling Pathway: Influence on Bone Remodeling
por: Mudri, Dunja, et al.
Publicado: (2023)

Therapeutic Perspectives of IL1 Family Members in Liver Diseases: An Update
por: Ćurčić, Ines Bilić, et al.
Publicado: (2022)

Antioxidant Pre-Treatment Reduces the Toxic Effects of Oxalate on Renal Epithelial Cells in a Cell Culture Model of Urolithiasis
por: Kizivat, Tomislav, et al.
Publicado: (2017)

Effect of COVID-19 on management of type 1 diabetes: Pushing the boundaries of telemedical healthcare
por: Bilic Curcic, Ines, et al.
Publicado: (2021)

Renal Benefits of SGLT 2 Inhibitors and GLP-1 Receptor Agonists: Evidence Supporting a Paradigm Shift in the Medical Management of Type 2 Diabetes
por: Ninčević, Vjera, et al.
Publicado: (2019)

Liraglutide Exerts Protective Effects by Downregulation of PPARγ, ACSL1 and SREBP-1c in Huh7 Cell Culture Models of Non-Alcoholic Steatosis and Drug-Induced Steatosis
por: Omanovic Kolaric, Tea, et al.
Publicado: (2022)

Renoprotective Effect of Liraglutide Is Mediated via the Inhibition of TGF-Beta 1 in an LLC-PK1 Cell Model of Diabetic Nephropathy
por: Ninčević, Vjera, et al.
Publicado: (2022)

Representation of CYP3A4, CYP3A5 and UGT1A4 Polymorphisms within Croatian Breast Cancer Patients’ Population
por: Bojanic, Kristina, et al.
Publicado: (2020)

Molecular Mechanisms Linking Empagliflozin to Renal Protection in the LLC-PK1 Model of Diabetic Nephropathy
por: Mihaljević, Vjera, et al.
Publicado: (2022)

Association of Wnt Inhibitors, Bone Mineral Density and Lifestyle Parameters in Women with Breast Cancer Treated with Anastrozole Therapy
por: Bojanić, Kristina, et al.
Publicado: (2018)

LIFESTYLE RISK FACTORS AND BONE MASS IN RECURRENT STONE-FORMING PATIENTS: A CROSS-SECTIONAL STUDY IN 144 SUBJECTS
por: Marić, Ivana, et al.
Publicado: (2019)

Biomarkers for Assessing Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus on Sodium–Glucose Cotransporter 2 Inhibitor Therapy
por: Khaznadar, Farah, et al.
Publicado: (2023)

Molecular Mechanisms of Resistance to Immune Checkpoint Inhibitors in Melanoma Treatment: An Update
por: Vukadin, Sonja, et al.
Publicado: (2021)

Models of Drug Induced Liver Injury (DILI) – Current Issues and Future Perspectives
por: Kuna, Lucija, et al.
Publicado: (2018)

Hepatitis C Virus, Insulin Resistance, and Steatosis
por: Kralj, Dominik, et al.
Publicado: (2016)

Obesity Paradox in Chronic Liver Diseases: Product of Bias or a Real Thing?
por: Curcic, Ines Bilic, et al.
Publicado: (2019)

Pathophysiological, Molecular and Therapeutic Issues of Nonalcoholic Fatty Liver Disease: An Overview
por: Marchisello, Simona, et al.
Publicado: (2019)

Psoriasis Severity—A Risk Factor of Insulin Resistance Independent of Metabolic Syndrome
por: Polic, Melita Vuksic, et al.
Publicado: (2018)

Hypothyroidism-Induced Nonalcoholic Fatty Liver Disease (HIN): Mechanisms and Emerging Therapeutic Options
por: Tanase, Daniela Maria, et al.
Publicado: (2020)

NONOBSTRUCTIVE CORONARY ARTERY DISEASE – CLINICAL RELEVANCE, DIAGNOSIS, MANAGEMENT AND PROPOSAL OF NEW PATHOPHYSIOLOGICAL CLASSIFICATION
por: Makarović, Zorin, et al.
Publicado: (2018)

Impact of Breast Density Awareness on Knowledge about Breast Cancer Risk Factors and the Self-Perceived Risk of Breast Cancer
por: Bojanic, Kristina, et al.
Publicado: (2020)

Targeting the Wnt Signaling Pathway in Liver Fibrosis for Drug Options: An Update
por: Duspara, Kristina, et al.
Publicado: (2021)

Coagulation and Endothelial Dysfunction Associated with NAFLD: Current Status and Therapeutic Implications
por: Ogresta, Doris, et al.
Publicado: (2022)

Nonalcoholic fatty liver disease and atrial fibrillation: possible pathophysiological links and therapeutic interventions
por: Haghbin, Hossein, et al.
Publicado: (2020)

Pretreatment of Garlic Oil Extracts Hampers Epithelial Damage in Cell Culture Model of Peptic Ulcer Disease
por: Kuna, Lucija, et al.
Publicado: (2022)

Fatty Pancreas: Linking Pancreas Pathophysiology to Nonalcoholic Fatty Liver Disease
por: Rugivarodom, Manus, et al.
Publicado: (2022)

Histopathologic Evaluation of Nonalcoholic Fatty Liver Disease in Hypothyroidism-Induced Rats
por: Demir, Şule, et al.
Publicado: (2016)

Nonalcoholic Fatty Liver Disease and Hypothyroidism: What You Need to Know
por: Bikeyeva, Viktoriya, et al.
Publicado: (2022)

Benign Fasciculation Syndrome and Migraine Aura without Headache: Possible Rare Side Effects of the BNT162b2 mRNA Vaccine? A Case Report and a Potential Hypothesis
por: Salai, Grgur, et al.
Publicado: (2022)

Semaglutide might be a key for breaking the vicious cycle of metabolically associated fatty liver disease spectrum?
por: Cigrovski Berkovic, Maja, et al.
Publicado: (2022)

Nonalcoholic fatty liver disease: epidemiology, pathogenesis and therapeutic implications
por: Andronescu, Craita Isabela, et al.
Publicado: (2018)

Preclinical Models and Promising Pharmacotherapeutic Strategies in Liver Fibrosis: An Update
por: Kolaric, Tea Omanovic, et al.
Publicado: (2023)

Shifting perspectives – interplay between non-alcoholic fatty liver disease and insulin resistance in lean individuals
por: Bilic-Curcic, Ines, et al.
Publicado: (2021)

Plasminogen activator inhibitor-1 concentrations and bone mineral density in postmenopausal women with type 2 diabetes mellitus
por: Canecki-Varžić, Silvija, et al.
Publicado: (2016)

Role of Oxidative Stress in Pathophysiology of Nonalcoholic Fatty Liver Disease
por: Masarone, Mario, et al.
Publicado: (2018)

Mechanistic Potential and Therapeutic Implications of Cannabinoids in Nonalcoholic Fatty Liver Disease
por: Dibba, Pratima, et al.
Publicado: (2018)

Nonalcoholic fatty liver disease: The role of quercetin and its therapeutic implications
por: Sotiropoulou, Maria, et al.
Publicado: (2021)

Impact of DAA Treatment on Cardiovascular Disease Risk in Chronic HCV Infection: An Update
por: Roguljic, Hrvoje, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7p4p6u1dj3u7itoin2sd2dkf7f